1800 244 735

Helpline (02) 9874 9777

Shining a spotlight on huntingtin: a tool to measure huntingtin-lowering in real time

A recent addition to the Huntington’s disease research toolkit lets us “see” how well huntingtin lowering drugs are working in the brains of HD animal models. An international collaboration of scientists from Belgium, Germany, the U.S.A. and the U.K. tested their recently developed tool, called a PET ligand, in HD mouse models. When these mice were treated with a huntingtin lowering therapy, the researchers were able to track how well the treatment was working.

What are PET ligands and why do we need one in the HD research toolkit?

PET ligands or PET tracers are chemical tools which let scientists and clinicians “see” inside different parts of your body. Once a person has been treated with a PET ligand, usually by swallowing a liquid or getting an IV injection, images are taken in a PET scanner, and a specific region or feature of the body will light up. This method is often used in cancer, heart disease, and brain disorders at regular intervals to help clinicians make their diagnosis, track disease progression, or assist in understanding how well a treatment might be working.

People with HD have an expanded form of the huntingtin gene which makes a toxic form of the huntingtin protein. This toxic form of the protein can’t assemble properly and forms clumps which build up over time. Many different companies and organisations are researching huntingtin-lowering drugs, which aim to reduce the clumps or the amount of the toxic huntingtin protein made. These drugs are under study in the lab and the clinic and come in different forms, including anti-sense oligonucleotides, gene therapy, and splice modulating approaches, all of which we reviewed here. The PET ligand in this recent investigation, which we have also written about previously, binds to toxic huntingtin clumps, and can be used to visualize them. This could be useful for tracking the buildup of huntingtin in a person’s brain over time, as well as how huntingtin levels change in response to huntingtin-lowering drugs.

The idea of using a PET ligand to track HD therapies is attractive for a number of reasons. Firstly, the procedure is non-invasive so it could offer a less burdensome way to track how huntingtin levels are changing compared to current methods, which involve analysing spinal fluid collected by lumbar puncture. Secondly, PET ligands would allow us to see exactly which brain regions have what level of huntingtin lowering, whereas measuring spinal fluid is only a proxy for what is happening in the brain as a whole. Thirdly, PET ligands would give a specific readout for the mutant form of the huntingtin protein whereas most current methods measure the total huntingtin levels – normal and toxic forms of the protein.

PET ligands can help us study the progression of HD-like symptoms in animal models

The authors of this recent paper first assessed how well the PET ligand could bind the toxic protein clumps in dissected brain specimens from different HD mouse models. They showed that the PET ligand lit up more and more in different brain regions as the HD mice got older, whereas the brains of mice without HD stayed dark. This paralleled the appearance of huntingtin clumps that could be seen using a nifty “stain” to look at them under a microscope.

They then showed that the PET ligand was binding the exact same clumps in brain samples from HD mouse models and also in a post-mortem brain sample from a patient with HD. This is good news; it means the PET ligand is binding the expected target – the toxic huntingtin clumps.

The researchers then looked at how the PET ligand was able to track signs of HD in living mouse models over the course of their lifespan. PET scans were taken at 4 time points and in the normal mice, no changes were seen, but for HD model mice, their brains lit up over time, indicating the build-up of the toxic clumps of huntingtin protein.

Tracking the effects of huntingtin lowering treatments in the brain in real time

To see whether the new PET ligand would be useful for measuring the effectiveness of HD therapies, different HD mouse models were treated with a huntingtin-lowering drug. The drug used in this study is a one-shot gene therapy where a virus is injected into the brain. HDBuzz wrote about this type of huntingtin lowering drug, called a ZFP, as a possible treatment for HD and although they show promise in lab models, they have not yet been tested in people in a clinical trial.

To monitor the effects of the ZFP over time, the HD mice received the real ZFP treatment in one side of their brain, and a dummy, or “control” treatment, in the other. A series of PET scans over time showed that around the region of the brain where the real ZFP had been injected, there were fewer clumps of toxic huntingtin build up compared to the dummy treated side. Giving the ZFP drug at a younger age was more effective than giving it later in life. This finding is important, as it suggests that perhaps huntingtin-lowering treatments may work best at the very early stages of disease.

In addition to looking at the huntingtin clumps with the new PET ligand, the team also looked at markers for specific types of brain cells called medium spiny neurons. In people with HD, this type of brain cell is damaged as the disease progresses. Mice treated with the huntingtin lowering ZFP had more signs of healthy medium spiny neurons than the control mice, which might indicate that reducing levels of toxic huntingtin protein could protect nerve cells.

Importantly, the scientists reproduced their findings in yet another HD mouse model, with an additional method of huntingtin-lowering. They also ran many important control experiments to prove that their experimental tools – HD animals, huntingtin-lowering treatments, and PET ligands – were working properly. The key takeaway from all of these experiments is that this new PET ligand is useful to measure clumps of toxic huntingtin in multiple models treated with different drugs over time. Furthermore, the PET ligands confirm that huntingtin-lowering treatments work best when given early in the course of disease.

What’s next for huntingtin PET ligands?

While its good news that this tool can be used to track symptoms and can also let us “see” the effects of huntingtin lowering treatments in mouse models of HD, what remains to be seen is if these tools are as useful in people with HD. A study is already underway to test that the huntingtin PET ligand is safe in humans. If it proves safe, subsequent studies will need to show this tool can be used to track the progression of HD symptoms in people. Critically, HD researchers will be very keen to know if the PET ligand can be used to monitor how huntingtin-lowering drugs might slow or interrupt the accumulation of the toxic clumps in humans.

The authors of this paper also highlight a number of other challenges with using this PET ligand at present. Most critically, we also don’t know yet how measuring huntingtin levels with the PET ligand compares to the currently used method of analysing the spinal fluid – a head-to-head analysis of these two approaches will be essential for scientists to figure out what all these different readouts might tell us.

We expect there will be more discussion about the huntingtin PET ligand at the upcoming CHDI meeting, so watch this space for more updates.

Latest Research Articles

Disappointing news from Novartis about branaplam and the VIBRANT-HD trial

Published date: 9 December, 2022

The pharmaceutical company Novartis has released a community update which announces that they are ending development of branaplam, a huntingtin lowering drug, for possible treatment in Huntington’s disease (HD). This news comes following recent bad news about side effects of branaplam in HD patients, being tested in the VIBRANT-HD clinical trial, dosing of which was ... Read more

Update on the PTC Therapeutics PIVOT-HD Trial

Published date: 2 November, 2022

Recruitment of participants into the US arm of the PTC Therapeutics PIVOT-HD trial has been paused. Since this announcement, there have been a lot of different (and confusing!) headlines about the pause in recruitment. In this article, we will lay out what is going on and what this announcement means. What is the aim of ... Read more

Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials

Published date: 30 September, 2022

In the past week or so, during and following a big HD research conference, two companies developing medicines for Huntington’s disease announced news about their huntingtin-lowering drugs. First, the pharmaceutical company Roche announced plans for a new clinical trial of tominersen. Then, the genetic medicines company Wave Life Sciences shared early data showing that its ... Read more

Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps

Published date: 8 September, 2022

A group of scientists from the EPFL in Lausanne, Switzerland have published a paper in the Journal of the American Chemical Society, describing clumps made up of a fragment of the huntingtin protein. A word that’s commonly used to describe these is “aggregates.” Using very powerful microscopes, the team was able to zoom in and ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 4

Published date: 2 September, 2022

DNA repair and CAG repeat instability The effect of HTT lowering on CAG repeat expansions Welcome to last day of the @hdfcures conference! We’ll only be sharing a few talks from today’s sessions, which focus on DNA repair. The first is from HDBuzz’s very own Jeff Carroll! Jeff will be sharing his work on HTT ... Read more

Hereditary Disease Foundation (HDF) conference 2022 – Day 3

Published date: 1 September, 2022

Pre-clinical work moving toward trials New tools to lower HTT showing promise in animal models Welcome back! The first talk we will be tweeting about today is from Anastasia Khvorova, who will be telling us about her teams work on lowering of Huntingtin using technology called RNAi. One of the problems in studying drug delivery ... Read more